Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus fractionated stereotactic radiotherapy for second-line and later advanced NSCLC with brain metastases (real-world study)
ChiCTR2600125084Phase 4Not yet recruiting
- Sponsor
- Pingmei Shenma Medical Group General Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Pingmei Shenma Medical Group General Hospital. Primary endpoint: Intracranial progression-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600125084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125084.